13D Filing: Sarissa Capital Management and Apricus Biosciences Inc. (APRI)

Page 1 of 7

Apricus Biosciences Inc. (NASDAQ:APRI): Alex Denner’s Sarissa Capital Management filed an amended 13D.

You can check out Sarissa Capital Management’s latest holdings and filings here.

Please follow Sarissa Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Sarissa Capital Management or update its stock holdings.

Follow Alex Denner's Sarissa Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Sarissa Capital Management 8 2,120,361 10 2,120,361 2,120,361 13.5 %
Alexander J. Denner 8 2,120,361 10 2,120,361 2,120,361 13.5 %
Sarissa Capital Offshore Master Fund 2,120,361 9 2,120,361 11 2,120,361 13.5 %

Follow Alex Denner's Sarissa Capital Management

Page 1 of 7 – SEC Filing

Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Apricus Biosciences, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
(CUSIP Number)
Mark DiPaolo
General Counsel
Sarissa Capital Management LP
660 Steamboat Road
Greenwich, CT 06830
With a copy to:
Russell Leaf
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
January 31, 2018
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be  subject to all other  provisions of the Act  (however, see the Notes).

Follow Seelos Therapeutics Inc. (NASDAQ:SEEL)

Page 1 of 7